# A Study to Evaluate Pharmacokinetic/Pharmacodynamic Drug-drug Interaction and Safety/Tolerability Between RLD2202 and RLD2203

> **NCT05481307** · PHASE1 · COMPLETED · sponsor: **Hanmi Pharmaceutical Company Limited** · enrollment: 24 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** RLD2202
- **DRUG:** RLD2203

## Key facts

- **NCT ID:** NCT05481307
- **Lead sponsor:** Hanmi Pharmaceutical Company Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-08-02
- **Primary completion:** 2022-10-25
- **Final completion:** 2022-10-25
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2023-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05481307

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05481307, "A Study to Evaluate Pharmacokinetic/Pharmacodynamic Drug-drug Interaction and Safety/Tolerability Between RLD2202 and RLD2203". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT05481307. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*